-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Myelodysplastic syndromes (MDS, Myelodysplastic syndromes) are age-related myeloid neoplasms with an increased risk of progression to acute myeloid leukemia (AML).
In Myelodysplastic Syndrome (MDS), the inability of the patient's body to produce blood cells effectively may predispose the patient to develop acute myeloid leukemia.
Scientists have discovered a specific inflammatory signal associated with the progression of leukemia
Image credit: Journal of Clinical Investigation (2022).
In the current study, the researchers conducted an in-depth study of genetically engineered mice with diseases closely related to MDS.
Based on the results of the mouse study, the researchers analyzed the bone marrow characteristics of MDS patients and found that the expression of two receptors for IL-6 was significantly increased in high-risk MDS patients, but in patients with acute myeloid Not in low-risk patients with leukemia
Taken together, these findings may suggest that targeting the IL-6 signaling pathway may hold promise as a potential therapy to prevent progression from MDS to acute myeloid leukemia in human patients
Original source:
Yang Mei, Kehan Ren, Yijie Liu, et al.